|
1
|
Hanna KS: A review of checkpoint
inhibitors in the management of renal cell carcinoma. J Oncol Pharm
Pract. 26:445–458. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abdellah A, Selma K, Elamin M, Asmae T,
Lamia R, Abderrahmane M, Sanaa el M, Hanan E, Tayeb K and
Noureddine B: Renal cell carcinoma in children: Case report and
literature review. Pan Afr Med J. 20:842015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abdulfatah E, Kennedy JM, Hafez K,
Davenport MS, Xiao H, Weizer AZ, Palapattu GS, Morgan TM, Mannan R,
Wang XM, et al: Clinicopathological characterisation of renal cell
carcinoma in young adults: A contemporary update and review of
literature. Histopathology. 76:875–887. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gray RE and Harris GT: Renal cell
carcinoma: Diagnosis and management. Am Fam Physician. 99:179–184.
2019.PubMed/NCBI
|
|
5
|
Makhov P, Joshi S, Ghatalia P, Kutikov A,
Uzzo RG and Kolenko VM: Resistance to systemic therapies in clear
cell renal cell carcinoma: Mechanisms and management strategies.
Mol Cancer Ther. 17:1355–1364. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Price M, Wu CC, Genshaft S, Sadow PM, Xie
L, Shepard JO and McDermott S: Imaging and management of
intrathoracic renal cell carcinoma metastases. AJR Am J Roentgenol.
210:1181–1191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Adibi M, Thomas AZ, Borregales LD, Matin
SF, Wood CG and Karam JA: Surgical considerations for patients with
metastatic renal cell carcinoma. Urol Oncol. 33:528–537. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu X, Zhang M, Liu X, Sun H, Guo Z, Tang
X, Wang Z, Li J, Li H, Sun W and Zhang Y: Urine metabolomics for
renal cell carcinoma (RCC) prediction: Tryptophan metabolism as an
important pathway in RCC. Front Oncol. 9:6632019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Watson DC, Bayik D, Srivatsan A,
Bergamaschi C, Valentin A, Niu G, Bear J, Monninger M, Sun M,
Morales-Kastresana A, et al: Efficient production and enhanced
tumor delivery of engineered extracellular vesicles. Biomaterials.
105:195–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qin Z, Xu Q, Hu H, Yu L and Zeng S:
Extracellular vesicles in renal cell carcinoma: Multifaceted roles
and potential applications identified by experimental and
computational methods. Front Oncol. 10:7242020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grange C, Brossa A and Bussolati B:
Extracellular vesicles and carried miRNAs in the progression of
renal cell carcinoma. Int J Mol Sci. 20:18322019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sheehan C and D'Souza-Schorey C:
Tumor-derived extracellular vesicles: Molecular parcels that enable
regulation of the immune response in cancer. J Cell Sci.
132:jcs2350852019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma P, Pan Y, Li W, Sun C, Liu J, Xu T and
Shu Y: Extracellular vesicles-mediated noncoding RNAs transfer in
cancer. J Hematol Oncol. 10:572017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu X, Hao Y, Yu W, Yang X, Luo X, Zhao J,
Li J, Hu X and Li L: Long non-coding RNA emergence during renal
cell carcinoma tumorigenesis. Cell Physiol Biochem. 47:735–746.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y and Tang L: The application of
lncRNAs in cancer treatment and diagnosis. Recent Pat Anticancer
Drug Discov. 13:292–301. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao M, Wang S, Li Q, Ji Q, Guo P and Liu
X: MALAT1: A long non-coding RNA highly associated with human
cancers. Oncol Lett. 16:19–26. 2018.PubMed/NCBI
|
|
17
|
Li Z, Ma Z and Xu X: Long non-coding RNA
MALAT1 correlates with cell viability and mobility by targeting
miR-22-3p in renal cell carcinoma via the PI3K/Akt pathway. Oncol
Rep. 41:1113–1121. 2019.PubMed/NCBI
|
|
18
|
Qiu JJ, Lin XJ, Tang XY, Zheng TT, Lin YY
and Hua KQ: Exosomal metastasis-associated lung adenocarcinoma
transcript 1 promotes angiogenesis and predicts poor prognosis in
epithelial ovarian cancer. Int J Biol Sci. 14:1960–1973. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Essandoh K, Yang L, Wang X, Huang W, Qin
D, Hao J, Wang Y, Zingarelli B, Peng T and Fan GC: Blockade of
exosome generation with GW4869 dampens the sepsis-induced
inflammation and cardiac dysfunction. Biochim Biophys Acta.
1852:2362–2371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu H, Brannon AR, Reddy AR, Alexe G,
Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: With
application to clear cell renal cell carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei JX, Lv LH, Wan YL, Cao Y, Li GL, Lin
HM, Zhou R, Shang CZ, Cao J, He H, et al: Vps4A functions as a
tumor suppressor by regulating the secretion and uptake of exosomal
microRNAs in human hepatoma cells. Hepatology. 61:1284–1294. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yeon JH, Jeong HE, Seo H, Cho S, Kim K, Na
D, Chung S, Park J, Choi N and Kang JY: Cancer-derived exosomes
trigger endothelial to mesenchymal transition followed by the
induction of cancer-associated fibroblasts. Acta Biomater.
76:146–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan L, Liang W, Fu M, Huang ZH, Li X,
Zhang W, Zhang P, Qian H, Jiang PC, Xu WR and Zhang X:
Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes
gastric cancer progression. J Cancer Res Clin Oncol. 143:991–1004.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang H, Li W, Gu W, Yan Y, Yao X and
Zheng J: MALAT1 accelerates the development and progression of
renal cell carcinoma by decreasing the expression of miR-203 and
promoting the expression of BIRC5. Cell Prolif. 52:e126402019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhai W, Ma J, Zhu R, Xu C, Zhang J, Chen
Y, Chen Z, Gong D, Zheng J, Chen C, et al: MiR-532-5p suppresses
renal cancer cell proliferation by disrupting the ETS1-mediated
positive feedback loop with the KRAS-NAP1L1/P-ERK axis. Br J
Cancer. 119:591–604. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tun HW, Marlow LA, von Roemeling CA,
Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ and
Copland JA: Pathway signature and cellular differentiation in clear
cell renal cell carcinoma. PLoS One. 5:e106962010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xu R, Rai A, Chen M, Suwakulsiri W,
Greening DW and Simpson RJ: Extracellular vesicles in
cancer-implications for future improvements in cancer care. Nat Rev
Clin Oncol. 15:617–638. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Becker A, Thakur BK, Weiss JM, Kim HS,
Peinado H and Lyden D: Extracellular vesicles in cancer:
Cell-to-cell mediators of metastasis. Cancer Cell. 30:836–848.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li YJ, Wu JY, Hu XB, Wang JM and Xiang DX:
Autologous cancer cell-derived extracellular vesicles as
drug-delivery systems: A systematic review of preclinical and
clinical findings and translational implications. Nanomedicine
(Lond). 14:493–509. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen J, Fei X, Wang J and Cai Z:
Tumor-derived extracellular vesicles: Regulators of tumor
microenvironment and the enlightenment in tumor therapy. Pharmacol
Res. 159:1050412020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Syn N, Wang L, Sethi G, Thiery JP and Goh
BC: Exosome-mediated metastasis: From epithelial-mesenchymal
transition to escape from immunosurveillance. Trends Pharmacol Sci.
37:606–617. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Z, Zhu X and Huang S: Extracellular
vesicle long non-coding RNAs and circular RNAs: Biology, functions
and applications in cancer. Cancer Lett. 489:111–120. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long noncoding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hardin H, Helein H, Meyer K, Robertson S,
Zhang R, Zhong W and Lloyd RV: Thyroid cancer stem-like cell
exosomes: Regulation of EMT via transfer of lncRNAs. Lab Invest.
98:1133–1142. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang LT, Wan CH, Guo QH, Yang SJ, Wu JD
and Cai J: Long noncoding RNA metastasis-associated lung
adenocarcinoma transcript 1 (MALAT1) promotes renal cell carcinoma
progression via sponging miRNA-429. Med Sci Monit. 24:1794–1801.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen S, Ma P, Zhao Y, Li B, Jiang S, Xiong
H, Wang Z, Wang H, Jin X and Liu C: Biological function and
mechanism of MALAT-1 in renal cell carcinoma proliferation and
apoptosis: role of the MALAT-1-Livin protein interaction. J Physiol
Sci. 67:577–585. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo Y, Liu F, Yan C, Qu W, Zhu L, Guo Z,
Zhou F and Zhang W: Long non-coding RNA CASC19 sponges microRNA-532
and promotes oncogenicity of clear cell renal cell carcinoma by
increasing ETS1 expression. Cancer Manag Res. 12:2195–2207. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kotarba G, Krzywinska E, Grabowska AI,
Taracha A and Wilanowski T: TFCP2/TFCP2L1/UBP1 transcription
factors in cancer. Cancer Lett. 420:72–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fanelli GN, Gasparini P, Coati I, Cui R,
Pakula H, Chowdhury B, Valeri N, Loupakis F, Kupcinskas J,
Cappellesso R and Fassan M: long-noncoding RNAs in gastroesophageal
cancers. Noncoding RNA Res. 3:195–212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zaravinos A, Lambrou GI, Mourmouras N,
Katafygiotis P, Papagregoriou G, Giannikou K, Delakas D and Deltas
C: New miRNA profiles accurately distinguish renal cell carcinomas
and upper tract urothelial carcinomas from the normal kidney. PLoS
One. 9:e916462014. View Article : Google Scholar : PubMed/NCBI
|
